Sight Sciences (NASDAQ: SGHT) awarded $55.4M and 10% Hydrus royalty

Rhea-AI Filing Summary

Sight Sciences, Inc. announced that a U.S. District Court entered a Final Judgment in its patent case against Alcon, awarding the company $55.4 million in total monetary damages and confirming that the asserted patent claims are valid and were willfully infringed.

The award includes $34.0 million in past damages through April 26, 2024, $14.7 million in supplemental damages through March 31, 2026, and $6.8 million in pre‑judgment and post‑judgment interest through April 17, 2026. The judgment also grants an ongoing 10% royalty on Hydrus Microstent revenue until the last of the patents expires. However, Alcon may appeal, and Sight Sciences will not receive any monetary damages unless appeals conclude or the appeal period ends without appeal, and certain patent reexamination outcomes could affect its ability to collect.

Positive

• Final Judgment with monetary award: Sight Sciences was awarded $55.4 million in total damages, including past and supplemental damages plus pre‑ and post‑judgment interest tied to Hydrus Microstent sales.
• Ongoing royalty stream: The company secured an ongoing 10% royalty on Hydrus revenue through expiration of the last asserted patent, creating potential recurring cash inflows if the judgment becomes final.

Negative

• Appeal risk delays cash realization: Sight Sciences will not receive monetary damages unless Alcon’s appeal rights are exhausted with a favorable, final judgment, or the appeal period passes without appeal.
• Patent reexamination risk: An adverse, final and non‑appealable decision in ex parte reexaminations of the asserted patent claims, if issued before a favorable final litigation judgment, could negatively affect the company’s ability to collect on the award.

Insights

Litigation and valuation analyst

Court awards Sight Sciences $55.4M plus a 10% Hydrus royalty, but payment depends on appeals.

The judgment confirms Sight Sciences’ asserted patent claims as valid and willfully infringed, with $55.4M in total damages and an ongoing 10% royalty on Hydrus revenue. This creates a potentially meaningful future cash stream tied to Alcon’s Hydrus sales.

However, Alcon can appeal to the Federal Circuit, and Sight Sciences will not receive damages unless appeals are exhausted or not pursued with a favorable, final outcome. The filing also notes that adverse, final ex parte reexamination decisions on the asserted patents, if entered before a favorable litigation judgment becomes final, could negatively affect collection. During any appeal, interest and royalties continue to accrue under the judgment terms.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Total damages awarded: $55.4 million Past damages: $34.0 million Supplemental damages: $14.7 million +2 more

5 metrics

Total damages awarded $55.4 million Final Judgment in patent litigation against Alcon

Past damages $34.0 million From first Hydrus sale through April 26, 2024

Supplemental damages $14.7 million From April 26, 2024 Verdict Date through March 31, 2026

Pre- and post-judgment interest $6.8 million Interest through April 17, 2026

Ongoing royalty rate 10% of Hydrus revenue Through expiration of the last asserted patent

Key Terms

Final Judgment, willfully infringed, ongoing royalty, pre-judgment and post-judgment interest, +1 more

5 terms

Final Judgment legal

"the Court entered its final judgment (the “Final Judgment”) regarding the patent infringement case"

willfully infringed legal

"the Patent claims asserted by the Company at trial were valid and were willfully infringed by Alcon"

ongoing royalty financial

"the Final Judgment awarded the Company an ongoing royalty of 10% of Hydrus revenue"

An ongoing royalty is a recurring payment made by a company to a rights holder—often for patents, trademarks, or creative work—calculated as a percentage of sales or a set fee tied to product use. Think of it like paying a toll each time you use a patented road: it reduces per-unit profit but can grant access to valuable technology or brands. Investors care because ongoing royalties affect future cash flow, margins, and the company’s long-term cost structure and valuation.

pre-judgment and post-judgment interest financial

"inclusive of ... $6.8 million in pre-judgment and post-judgment interest through April 17, 2026"

ex parte reexamination legal

"ex parte reexamination proceedings initiated by Alcon (seeking to invalidate the Patent claims we asserted at trial)"

An ex parte reexamination is a formal review by a patent office that rechecks whether an issued patent should have been granted, based on prior public information. Think of it as a one-sided second opinion where the challenger can ask for the review but, once it starts, the patent holder mainly responds through written submissions rather than ongoing back-and-forth; the outcome can quietly weaken, cancel, or confirm patent protection, which matters to investors because patents often underpin a company’s competitive edge, revenue prospects and legal risk.

Understanding 8-K Material Events →

0001531177false00015311772026-04-222026-04-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 22, 2026

Sight Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40587	80-0625749
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4040 Campbell Avenue Suite 100
Menlo Park, California				94025
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 877 266-1144

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		SGHT		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On April 22, 2026, Sight Sciences, Inc. (the “Company”) received notification that the U.S. District Court for the District of Delaware (the “Court”) entered its final judgment (the “Final Judgment”) regarding the patent infringement case (the “Litigation”) filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, “Alcon”). The Company had asserted that Alcon’s sale of the Hydrus® Microstent (“Hydrus”) infringed three of the Company’s patents. The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328 (the “Patents”). The Final Judgment upheld the trial jury’s findings that the Patent claims asserted by the Company at trial were valid and were willfully infringed by Alcon.

The Final Judgment also awarded total monetary damages to the Company of $55.4 million. This award is inclusive of: (i) $34.0 million in past damages for the period from the first commercial sale of Hydrus through April 26, 2024, the date the trial jury rendered its verdict (the “Verdict Date”), (ii) $14.7 million in supplemental damages for the period from the Verdict Date through March 31, 2026, and (iii) $6.8 million in pre-judgment and post-judgment interest through April 17, 2026. In addition, the Final Judgment awarded the Company an ongoing royalty of 10% of Hydrus revenue through the date of expiration of the last of the Patents. The Final Judgment is subject to appeal by Alcon.

Absent settlement, no monetary damages will be received by the Company unless and until (i) Alcon exhausts its rights to appeal to the United States Court of Appeals for the Federal Circuit and the appeals court affirms a judgment in the Company’s favor, or (ii) the time for filing an appeal has passed. During the pendency of any such appeal, interest and royalties will continue to accrue in accordance with the terms of the Final Judgment. In addition, if an adverse, final and non-appealable judgment from one or more of the ex parte reexamination proceedings initiated by Alcon (seeking to invalidate the Patent claims we asserted at trial) is entered by the Federal Circuit Court of Appeals before a favorable final and non-appealable judgment from the Litigation is entered by that same appeals court, it could negatively affect the Company’s ability to collect on the Final Judgment.

The information in Item 7.01 of this Current Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description of Exhibit
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Sight Sciences, Inc.
Date:	April 23, 2026	By:	/s/ James Rodberg
			Chief Financial Officer

FAQ

What did Sight Sciences (SGHT) announce regarding its patent case against Alcon?

Sight Sciences reported a U.S. District Court Final Judgment in its favor in a patent infringement case against Alcon. The judgment confirms the asserted patents’ validity and willful infringement and grants $55.4 million in damages plus an ongoing royalty on Hydrus Microstent revenue.

How much in total damages did Sight Sciences (SGHT) receive in the Final Judgment?

The Court awarded Sight Sciences $55.4 million in total monetary damages. This includes $34.0 million in past damages, $14.7 million in supplemental damages, and $6.8 million in pre‑ and post‑judgment interest through April 17, 2026, all tied to Hydrus Microstent sales.

What ongoing royalty did Sight Sciences (SGHT) secure on Alcon’s Hydrus Microstent sales?

The Final Judgment awards Sight Sciences an ongoing 10% royalty on revenue from Alcon’s Hydrus Microstent. This royalty runs through the expiration date of the last of the asserted U.S. patents, potentially providing recurring revenue if the judgment becomes final and enforceable.

When will Sight Sciences (SGHT) actually receive the $55.4 million in damages?

Sight Sciences will not receive monetary damages immediately. Payment occurs only if Alcon’s appeal rights are fully exhausted with a favorable, final judgment for Sight Sciences, or the time to appeal passes without appeal, as outlined in the court’s Final Judgment provisions.

How could patent reexaminations affect Sight Sciences’ ability to collect the judgment?

Ex parte reexaminations initiated by Alcon seek to invalidate asserted patent claims. If an adverse, final and non‑appealable reexamination decision issues before a favorable, final litigation judgment from the Federal Circuit, the filing notes this outcome could negatively affect Sight Sciences’ ability to collect the awarded damages.

Will interest and royalties for Sight Sciences (SGHT) continue during Alcon’s potential appeal?

Yes. The company states that during any appeal period, interest and royalties will continue to accrue under the Final Judgment terms. Actual receipt of these amounts, however, still depends on a favorable, final and non‑appealable outcome or the lapse of Alcon’s appeal rights.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 26.4 KB